Possibilities of effective antitumor therapy of patients with chronic lymphocytic leukemia depending on the clinical and laboratory characteristics of the disease

Purpose: to determine the optimal therapy regimens in patients with CLL, depending on age, comorbidity, prognostic (genetic) factors, clinical picture. Materials and methods: analysis of case histories of 400 patients with CLL observed at the Rostov State Medical University, Ministry of Health of the Russian Federation from 2010 to 2020.

Results: Immunochemotherapy according to the FCR and FCR-Lite regimens has shown high efficiency in primary and pre-treated patients in terms of the frequency of achieving complete and partial remissions and achieving progression-free survival. In untreated patients, complete remissions were obtained in 61 (71.7%), partial remissions - in 14 (16.4%); among pre-treated patients, respectively - 40 (20.5%) and 65 (33.8%).

Conclusion: combination therapy according to the FCR and FCR-Lite regimens is an affordable and effective method of treatment for most patients with CLL. When the level of leukemic blood cells with 17p13 deletion is less than 15%, rituximab should be used in the first line of immunochemotherapy, and ibrutinib (imbruvica) in case of more than 15%. In mono-regimen, rituximab is effective in supportive - anti-relapse therapy and in the treatment of autoimmune complications.

1. Гематология: национальное руководство. Под ред. проф. О.А. Рукавицына. М.: ГЭОТАР–Медиа, 2015. ISBN 978-5-9704-3327-0

2. Hallek M., Fisher K., Fingerle-Rowson G. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomized, open-label, phase III trial. Lancet. 2010;(376):1164-1174. doi: 10.1016/S0140-6736(10)61381-5.

3. Rosenquist R., Cortese D., Bhoi S., Mansouri L., Gunnarson R. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? Leukemia & Lymphoma. 2013;54(11):2351–2364. doi: 10.3109/10428194.2013.783913.

4. Kaur Pr. Chronic Lymphocytic Leukemia. Springer International Publishing AG. 2018. Doi: 10.1007/978-3-319-70603-0, ISBN 978-3-319-70603-0.

5. Кондраковский П.М. Дубиков А.И., Дорошевская А.Ю. Нарушения в системе белка р53 и их влияние на патогенез хронических лимфопролиферативных заболеваний. Онкогематология. 2011;(3):65-75. Doi: 10.17650/1818-8346-2011-6-3-65-75

6. Rafei H., Kharfan-Dabaja M.A. Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. Hematology/Oncology and Stem Cell Therapy. 2018;(11):1–12. doi: 10.1016/j.hemonc.2017.04.002.

7. Никитин Е.А., Северина Н.А., Обухова Т.Н., Бидерман Б.В., Кисиличина Д.Г., Наумова Е.В. и др. Нарушения гена TP53 у больных хроническим лимфолейкозом. Клиническая онкогематология. 2012;5(4):316-322. eLIBRARY ID: 22483449.

8. Шатохин Ю.В., Зельцер А.Н., Снежко И.В., Сизякина Л.П., Шатохина О.Н. Хронический лимфолейкоз: причины резистентности к циторедукторной терапии. Цитокины и воспаление. 2018;17(1- 4):31-37. eLIBRARY ID: 416727019.

9. Колбин А.С., Вилюм И.А., Проскурин М.А., Балыкина Ю.Е. Фармакоэкономический анализ применения ибрутиниба в первой линии терапии хронического лимфолейкоза у пациентов с делецией 17р. Качественная клиническая практика. 2015;(1):32-43. eLIBRARY ID: 23597169

10. Moreno C., Byrd J.C., Hillmen P., O'Brien S., Barrientos J.C., Reddy N.M., et al. Ibrutinib in previously treated chronic lymphocytic leukemia: updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 2017, Abstract S769. EHA Library. 06/25/17;182056;S769.